Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $3.6 million.

  • Altimmune's Share-based Compensation rose 1546.46% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year increase of 726.24%. This contributed to the annual value of $14.4 million for FY2024, which is 3527.26% up from last year.
  • According to the latest figures from Q3 2025, Altimmune's Share-based Compensation is $3.6 million, which was up 1546.46% from $3.6 million recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Share-based Compensation peaked at $4.3 million during Q2 2024, and registered a low of $1.2 million during Q1 2021.
  • Over the past 5 years, Altimmune's median Share-based Compensation value was $2.7 million (recorded in 2023), while the average stood at $2.6 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 46671.99% in 2021, then tumbled by 1728.14% in 2025.
  • Altimmune's Share-based Compensation (Quarter) stood at $1.3 million in 2021, then surged by 43.44% to $1.9 million in 2022, then surged by 30.5% to $2.5 million in 2023, then skyrocketed by 35.84% to $3.4 million in 2024, then grew by 5.96% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $3.6 million for Q2 2025, and $4.0 million during Q1 2025.